Nova Mentis (OTC: NMLSF) Study Confirms Oral Microdose Psilocybin Treatment of Autism
VANCOUVER, BC, Feb. 16, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce […]